Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Proteinuria

Abate or applaud abatacept in proteinuric kidney disease?

T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Maxwell, L. J. & Singh, J. A. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J. Rheumatol. 37, 234–245 (2010).

    Article  CAS  Google Scholar 

  2. Yu, C.-C. et al. Abatacept in B7-1-positive proteinuric kidney disease. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1304572.

  3. Vincenti, F. et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 10, 535–546 (2010).

    Article  CAS  Google Scholar 

  4. Pestana, J. O. M. et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am. J. Transplant. 12, 630–639 (2012).

    Article  CAS  Google Scholar 

  5. Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952–960 (2011).

    Article  CAS  Google Scholar 

  6. Clement, L. C. et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat. Med. 17, 117–122 (2011).

    Article  CAS  Google Scholar 

  7. Reiser, J. et al. Induction of B7–1 in podocytes is associated with nephrotic syndrome. J. Clin. Invest. 113, 1390–1397 (2004).

    Article  CAS  Google Scholar 

  8. Ishimoto, T. et al. Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice. Nephrol. Dial. Transplant. 28, 1439–1446 (2013).

    Article  CAS  Google Scholar 

  9. Furie, R. et al. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, randomized, double-blind, placebo controlled phase II/III study [abstract]. Arthritis Rheum. 63 (Suppl. 10), a2469 (2011).

    Google Scholar 

  10. Cravedi, P., Kopp, J. B. & Remuzzi, G. Recent progress in the pathophysiology and treatment of FSGS recurrence. Am. J. Transplant. 13, 266–274 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jochen Reiser.

Ethics declarations

Competing interests

J. Reiser has pending or issued patents on novel kidney-protective therapies. He stands to gain royalties from their commercialization. N. Alachkar declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reiser, J., Alachkar, N. Abate or applaud abatacept in proteinuric kidney disease?. Nat Rev Nephrol 10, 128–130 (2014). https://doi.org/10.1038/nrneph.2013.276

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2013.276

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing